Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 11/20 | 0.64 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | MLLT1 | Q03111 | 3/20 | 0.37 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.37 |
| ▸ | F9 | P00740 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12418846 | 0.85 | NR3C1 (0.55) | NR3C1NAMPTMLLT1MLLT3F9 | |
| SCHEMBL12378920 | 0.81 | NR3C1 (0.76) | NR3C1 | |
| SCHEMBL2896278 | 0.75 | NR3C1 (0.47) | NR3C1 | |
| SCHEMBL2353904 | 0.75 | NR3C1 (0.46) | NR3C1 | |
| SCHEMBL30397330 | 0.70 | MLLT1 (0.41) | NR3C1NAMPTMLLT1MLLT3MAOB | |
| SCHEMBL10198841 | 0.70 | SLC6A2 (0.48) | NR3C1 | |
| SCHEMBL2900773 | 0.70 | CNR2 (0.42) | NR3C1 | |
| SCHEMBL12592391 | 0.70 | MEN1 (0.47) | NR3C1 | |
| SCHEMBL12592369 | 0.67 | NR3C1 (0.56) | NR3C1 | |
| SCHEMBL12592368 | 0.67 | NR3C1 (0.56) | NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994190-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994190-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100190820-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-29 | — | — | US | disclosed |
| US-20100190820-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-29 | — | — | US | disclosed |
| EP-2089389-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPA-B ACTIVITY | Bristol-Myers Squibb Company (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008057855-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-I, AND/OR NP-KAPPA-B ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057855-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-I, AND/OR NP-KAPPA-B ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190820-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NR0B1, NR3C1, NFRKB | NR3C1 2/4885NAMPT 4607/4885MLLT1 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.